BACKGROUND: Because persistent inflammation plays a dominant role in cystic fibrosis (CF), we assessed systemic and local upper airway responses during and after pulmonary exacerbation. METHODS: We followed a cohort of Pseudomonas aeruginosa-infected adult CF patients (n=16) over time in pulmonary exacerbation and in stable disease. Interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17A, IL-22, interferon-γ and TNFα levels were measured in sputum, nasal lavages and plasma. RESULTS: In CF patients IL-6 and IL-10 levels in nasal lavages were significantly increased in exacerbation compared with stable disease. Systemic IL-6 significantly correlated with CRP levels and FEV1 (%predicted), independently of disease status. Systemic IL-10 also correlated significantly with CRP and FEV1 (%predicted), but only in exacerbation. Other cytokines tested did not discriminate between exacerbation and stable disease. CONCLUSIONS: Determination of IL-6 and IL-10 in nasal lavages may provide a minimally invasive tool in the assessment of an exacerbation in CF.
BACKGROUND: Because persistent inflammation plays a dominant role in cystic fibrosis (CF), we assessed systemic and local upper airway responses during and after pulmonary exacerbation. METHODS: We followed a cohort of Pseudomonas aeruginosa-infected adult CFpatients (n=16) over time in pulmonary exacerbation and in stable disease. Interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17A, IL-22, interferon-γ and TNFα levels were measured in sputum, nasal lavages and plasma. RESULTS: In CF patientsIL-6 and IL-10 levels in nasal lavages were significantly increased in exacerbation compared with stable disease. Systemic IL-6 significantly correlated with CRP levels and FEV1 (%predicted), independently of disease status. Systemic IL-10 also correlated significantly with CRP and FEV1 (%predicted), but only in exacerbation. Other cytokines tested did not discriminate between exacerbation and stable disease. CONCLUSIONS: Determination of IL-6 and IL-10 in nasal lavages may provide a minimally invasive tool in the assessment of an exacerbation in CF.
Authors: M Kolpen; T Bjarnsholt; C Moser; C R Hansen; L F Rickelt; M Kühl; C Hempel; T Pressler; N Høiby; P Ø Jensen Journal: Clin Exp Immunol Date: 2014-07 Impact factor: 4.330
Authors: Alexis D Payton; Alexia N Perryman; Jessica R Hoffman; Vennela Avula; Heather Wells; Carole Robinette; Neil E Alexis; Ilona Jaspers; Julia E Rager; Meghan E Rebuli Journal: Am J Physiol Lung Cell Mol Physiol Date: 2022-03-23 Impact factor: 5.464
Authors: Sara Khanal; Megan Webster; Naiqian Niu; Jana Zielonka; Myra Nunez; Geoffrey Chupp; Martin D Slade; Lauren Cohn; Maor Sauler; Jose L Gomez; Robert Tarran; Lokesh Sharma; Charles S Dela Cruz; Marie Egan; Theresa Laguna; Clemente J Britto Journal: Eur Respir J Date: 2021-11-11 Impact factor: 33.795
Authors: Julia Hentschel; Manuela Jäger; Natalie Beiersdorf; Nele Fischer; Franziska Doht; Ruth K Michl; Thomas Lehmann; Udo R Markert; Klas Böer; Peter M Keller; Mathias W Pletz; Jochen G Mainz Journal: BMC Pulm Med Date: 2014-05-13 Impact factor: 3.317
Authors: Hannah K Bayes; Neil D Ritchie; Christopher Ward; Paul A Corris; Malcolm Brodlie; Thomas J Evans Journal: J Cyst Fibros Date: 2016-07-01 Impact factor: 5.482